Enterocolitis Associated with Immune Effector Cells Following BCMA-Targeted CAR T-Cell Therapy: Findings from a Multicenter Case Series - Summary - MDSpire
Advertisement
Enterocolitis Associated with Immune Effector Cells Following BCMA-Targeted CAR T-Cell Therapy: Findings from a Multicenter Case Series
To characterize the clinical course, pathology, and outcomes of immune effector cell-associated enterocolitis (IEC-EC) following BCMA-targeted CAR T-cell therapy in multiple myeloma patients, highlighting its significance as a late-onset complication.
Key Findings:
Nineteen patients were identified, with a median age of 68 years and a median follow-up of 473 days.
The incidence of IEC-EC was estimated at 4.3%; 84% experienced Grade 3 or higher diarrhea/colitis.
Delayed neurotoxicity preceded diarrhea in 26% of patients.
Treatment responses were limited, with high rates of hospitalization and a 37% overall mortality rate, primarily due to IEC-EC-related complications, including infections and intestinal perforation.
Interpretation:
IEC-EC is a significant late-onset complication of BCMA-directed CAR T-cell therapy, characterized by severe gastrointestinal dysfunction and high morbidity, often resistant to standard immunosuppressive treatments, necessitating improved management strategies.
Limitations:
The study is retrospective and may be subject to selection bias.
The small sample size limits the generalizability of findings and may overlook confounding factors.
Conclusion:
IEC-EC represents a serious complication of BCMA-CART, necessitating careful monitoring and management strategies to mitigate its impact on patient outcomes, and further research is needed to optimize treatment approaches.
by Sandra Susanibar-Adaniya, Benjamin A. Derman, Adam D. Cohen, Dan T. Vogl, Shambavi Richard, Adriana Rossi, Matthew J. Frigualt, Andrew J. Yee, Binod Dhakal, Noffar Bar
